D.A. Davidson & CO. Buys 300 Shares of Edwards Lifesciences Co. (NYSE:EW)

D.A. Davidson & CO. boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,033 shares of the medical research company’s stock after purchasing an additional 300 shares during the quarter. D.A. Davidson & CO.’s holdings in Edwards Lifesciences were worth $743,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. International Assets Investment Management LLC boosted its position in Edwards Lifesciences by 10,990.6% during the third quarter. International Assets Investment Management LLC now owns 163,919 shares of the medical research company’s stock worth $10,817,000 after purchasing an additional 162,441 shares during the period. Forsta AP Fonden boosted its position in Edwards Lifesciences by 12.0% during the third quarter. Forsta AP Fonden now owns 134,000 shares of the medical research company’s stock worth $8,843,000 after purchasing an additional 14,400 shares during the period. Smithbridge Asset Management Inc. DE boosted its position in shares of Edwards Lifesciences by 20.2% in the third quarter. Smithbridge Asset Management Inc. DE now owns 13,086 shares of the medical research company’s stock valued at $864,000 after acquiring an additional 2,202 shares during the period. Forbes J M & Co. LLP grew its stake in shares of Edwards Lifesciences by 6.1% in the third quarter. Forbes J M & Co. LLP now owns 5,610 shares of the medical research company’s stock valued at $370,000 after acquiring an additional 325 shares in the last quarter. Finally, abrdn plc grew its stake in shares of Edwards Lifesciences by 1.7% in the third quarter. abrdn plc now owns 1,311,844 shares of the medical research company’s stock valued at $85,847,000 after acquiring an additional 22,271 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on EW shares. The Goldman Sachs Group upped their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Citigroup upped their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Finally, Truist Financial restated a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $79.95.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock worth $2,002,829 in the last quarter. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Down 0.8 %

Shares of NYSE EW opened at $72.72 on Tuesday. The company has a 50 day simple moving average of $72.83 and a 200 day simple moving average of $70.13. The firm has a market cap of $42.89 billion, a PE ratio of 10.43, a price-to-earnings-growth ratio of 4.82 and a beta of 1.11. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.